A
3.59
-0.02 (-0.55%)
| Previous Close | 3.61 |
| Open | 3.62 |
| Volume | 859,522 |
| Avg. Volume (3M) | 1,042,837 |
| Market Cap | 687,413,184 |
| Price / Sales | 92.04 |
| Price / Book | 6.02 |
| 52 Weeks Range | |
| Earnings Date | 5 May 2025 - 8 May 2025 |
| Operating Margin (TTM) | -995.43% |
| Diluted EPS (TTM) | -0.380 |
| Quarterly Revenue Growth (YOY) | -26.60% |
| Total Debt/Equity (MRQ) | 6.28% |
| Current Ratio (MRQ) | 8.15 |
| Operating Cash Flow (TTM) | -64.85 M |
| Levered Free Cash Flow (TTM) | -41.56 M |
| Return on Assets (TTM) | -33.36% |
| Return on Equity (TTM) | -68.76% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Arbutus Biopharma Corporation | Mixed | Bullish |
AIStockmoo Score
1.0
| Analyst Consensus | 2.5 |
| Insider Activity | NA |
| Price Volatility | 2.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | 2.0 |
| Average | 1.00 |
|
Arbutus Biopharma Corp is a biopharmaceutical company. The company discovers, develops, and commercializes cures for patients suffering from Hepatitis B infection. The company is focused on developing a portfolio of drug candidates with multiple mechanisms of action and is also involved in licensing Lipid nanoparticle technology. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 22.03% |
| % Held by Institutions | 54.95% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Whitefort Capital Management, Lp | 31 Dec 2024 | 13,241,916 |
| Blackbarn Capital Partners Lp | 31 Dec 2024 | 2,341,871 |
| Rubric Capital Management Lp | 31 Dec 2024 | 1,681,090 |
| Adar1 Capital Management, Llc | 31 Dec 2024 | 1,554,802 |
| Rangeley Capital, Llc | 31 Dec 2024 | 1,459,000 |
| Fourworld Capital Management Llc | 31 Dec 2024 | 1,226,710 |
| 52 Weeks Range | ||
| Median | 5.00 (39.28%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Chardan Capital | 28 Mar 2025 | 5.00 (39.28%) | Buy | 3.50 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 23 Apr 2025 | Announcement | Arbutus to Present Imdusiran and AB-101 Data at EASL Congress 2025 |
| 27 Mar 2025 | Announcement | Arbutus Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update |
| 03 Mar 2025 | Announcement | Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |